Novo Nordisk has entered into a research and development collaboration with Life Edit Therapeutics to discover and develop next-generation gene editing therapies for rare genetic disorders as well as more prevalent cardiometabolic diseases. The collaboration, that could be worth up to US$1.92 B, allows for the development of up to seven programmes. This deal could represent a significant stride towards innovative therapies and underscores the immense potential of gene-editing technologies to advance the treatment of genetic diseases.